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1. Introduction 
Ischemic heart disease continues to be a leading cause of death in most countries, with the 
death rate in men almost twice as high as that of women. Following an ischemic event, the 
primary clinical strategy is to quickly restore blood flow to the heart muscle, myocardial 
reperfusion, using drug therapy (thrombolytics) or percutaneous coronary intervention. The 
damage that follows ischemia-reperfusion is triggered by increased production of oxygen 
free radicals at the time of reperfusion when blood flow is restored (Ambrosio et al. 1993; 
Marczin et al. 2003) and impaired myocardial antioxidant defences, leading to 
cardiomyocyte apoptosis and increased infarct size.  
Hyperglycaemia and high plasma levels of aldosterone are two critical factors that produce 
poor outcomes following an ischemic event and reperfusion strategies. Diabetes is now the 
fastest growing disease worldwide, and a public health concern globally given the aging 
population -currently affecting more than 240 million people worldwide, and the number is 
predicted to rise to more than 360 million by 2030, according to the World Health 
Organization. Global health expenditure on diabetes is estimated to rise to USD 490 billion 
(Zhang et al. 2010) and cardiovascular disease is the major cause of death. In adults with 
type 2 diabetes, cardiovascular disease is responsible for 65-75% of deaths due to 
myocardial infarction and end stage renal disease; and the age-adjusted relative risk for 
cardiovascular complications in type 1 diabetes may exceed that of type 2 (Nadeua et al. 
2010). Although first line treatment for diabetes is anti-hyperglycaemic agents, additional 
therapeutic strategies are needed. In addition, during hypoglycaemia there is an increase in 
aldosterone production (Adler et al. 2010) and there is emerging evidence of a relationship 
between aldosterone and insulin resistance.  
High plasma aldosterone levels during percutaneous coronary intervention double the risk 
of mortality and are an independent risk factor for mortality (Beygui et al. 2006). 
Inappropriately elevated aldosterone levels produce cardiac and vascular inflammation and 
fibrosis, leading to remodelling and disease via activation of mineralocorticoid receptors 
(MR) (Brilla et al. 1990; Young et al. 1995). Recent experimental studies (Mihailidou et al. 
2009) show that during myocardial ischemia-reperfusion, cardiac damage is aggravated by 
activation of mineralocorticoid receptors by both aldosterone (Fig.1) and cortisol (Fig. 2).  
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Reproduced from Mihailidou et al. (2009) with permission 
Fig. 1.  
 
Reproduced from Mihailidou et al. (2009) with permission  
Fig. 2.  
Current therapies, such as antagonism of the renin-angiotensin-system, mitigate the 
cardiorenal complications of diabetes but do not suppress aldosterone production. 
Aldosterone levels increase (“aldosterone breakthrough”) in 10-53% patients and recent 
studies suggest an association between aldosterone production and insulin resistance in 
normotensive subjects (Balkau et al. 1998), indicating aldosterone is an independent risk 
factor for myocardial damage. The results from RALES (Randomised ALdactone Evaluation 
Study, Pitt et al. 1999), EPHESUS (Eplerenone Post acute Myocardial Infarction HEart 
Failure SUrvival and efficacy Study, Pitt et al. 2003), and recently EMPHASIS-HF 
(Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure, Zannad et 
al. 2011) provide strong evidence that preventing MR activation increases survival and 
decreases hospitalization in patients with heart failure and acute myocardial infarction. In 
these trials 32% of patients were diabetic.  
Since patients with diabetes have a 2-3 fold increased risk of ischemic heart disease, any new 
drug therapy for lowering glucose levels in this population must be evaluated in terms of its 
safety for use in patients with cardiovascular disease. It would be advantageous if this 
medication is shown to have cardio-protective effects, and to ensure there isn’t aggravated 
cardiac damage following a heart attack. Glucagon-Like Peptide-1 (GLP-1) agonists are a 
relatively new class of anti-hyperglycaemic medications for the management of patients 
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with diabetes. These agents also elicit a cytoprotective effect on beta cells leading to 
preservation and survival of beta-cell mass (Tschen et al. 2009; 2011; Brubaker & Drucker 
2004). The impact of these new therapeutic agents on cardiovascular disease remains 
unclear. Controlled large clinical studies of GLP-1 agonists on cardiovascular outcomes 
following ischemic heart disease for patients with diabetes are currently in progress. 
Whether there is added benefit of combining GLP-1 agonists with a mineralocorticoid 
receptor antagonist has not been examined.   
Given the increasing aging populations globally, increased incidence of both type 1 and type 
2 diabetes and elevated mortality in patients with high plasma aldosterone levels, this 
chapter will provide a review of our current understanding of the incidence of ischemic 
heart disease in both type 1 and type 2 diabetes; mechanisms involved and new treatment 
strategies. These include the GLP-1 agonists and mineralocorticoid receptor antagonists as 
potential additional therapeutic strategies to reduce cardiovascular complications of 
diabetes. 
2. Ischemic heart disease and diabetes 
Cardiovascular disease is the major cause of disease burden and death globally and along 
with diabetes and cancer make up two-thirds of all deaths globally, according to the World 
Health Organization’s report for 2011 World Health Statistics. The impact of hyperglycemia 
in patients with acute myocardial infarction (AMI) varies with age, with higher risk for in-
hospital mortality among younger patients (Nicolau et al. 2011). Hyperglycemia was 
associated with 7.6-fold increased odds for in-hospital death in patients younger than 50 
years, compared with a 3.5-fold increased risk in those aged 50-60 years. Worldwide, there is 
a higher risk of diabetes or cardiovascular disease in rural areas than in urban areas (Wan et 
al. 2007). The prevalence of type 2 diabetes is increasing dramatically due to the aging 
population, obesity and physical inactivity. Although Type 1 diabetes is less common and 
usually has onset in younger subjects, age-adjusted relative risk for cardiovascular 
complications in type 1 may exceed type 2 diabetes (Nadeau et al. 2010).  
Patients with either type 1 or type 2 diabetes have significantly higher mortality and 
morbidity following acute myocardial infarction than do the rest of the population, with 
increasing focus on hyperglycemia contributing directly to the excessive cardiovascular risk 
in patients with diabetes. The hazard ratio for major cardiovascular disease (CVD) was 
reported to be 3.6 (95% CI 2.9–4.5) in men with type 1 diabetes compared with those without 
diabetes (Soedamah-Muthu et al. 2006), while men with type 2 diabetes, the hazard ratio 
was 3.3 (95% CI 2.5– 4.5) and 10.1 (6.7–17.4) in women. (Juutilainen et al. 2008). Clinically, 
elevated but non-diabetic blood glucose levels increase cardiovascular mortality risk (Balkau 
et al. 1998). During myocardial reperfusion injury, hyperglycaemia increases cardiomyocyte 
apoptosis in both human (Frustaci et al.2000) and animal models (Fiordaliso et al. 2000; Sheu 
et al. 2007) of diabetes. Restoring blood flow to the ischemic myocardium is accompanied be 
increased oxygen free radicals (Ambrosio et al. 1993; Brown et al. 1988) and impaired 
myocardial antioxidant defence capacity leading to tissue injury (Leichtweis et al 2001), and 
therefore additional therapeutic strategies are needed to complement glycemic control.  
Inflammation also promotes reperfusion injury (Kawaguchi et al. 2011), and both type 1 and 
type 2 diabetes include inflammatory components: type 1 diabetes is an auto-immune 
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disease (Atkinson and Eisenbarth, 2001), and more recently type 2 diabetes has also been 
considered an auto-inflammatory condition (Donath and Shoelson, 2011) leading to an 
increase production of pro-inflammatory mediators including pro-inflammatory cytokines 
IL-6 and TNF-α. Activation of TNF-, activates apoptosis, and amplifies the innate immune 
response. The innate immune response has been identified to interact with danger 
associated molecular patterns (DAMPs) found on proteins released by necrotic cells 
following ischemia-reperfusion that include HMGB1 and heat shock proteins via toll like 
receptors (TLRs). This interaction activates NFsignalling promoting innate immune cell 
infiltration into the myocardium, increased cytokine production and increased pro-
apoptotic activity through caspase 3/7 and hence further aggravating reperfusion injury 
(Arslan et al., 2010). Additionally CD4+ T-cells have been identified to infiltrate the 
myocardium during reperfusion and through the release of cytokine IFN- promote 
infiltration of innate immune cells, in particular macrophages and neutrophils, the effector 
cells of the immune response to reperfusion injury (Yang et al., 2006). This increase in 
adaptive and innate immune responses in diabetes promotes activity of the complement 
system, which also further aggravates reperfusion injury (van der Pals et al., 2010).  
3. Mechanisms involved in hyperglycaemia-aggravated ischemic heart 
disease 
During prolonged ischemia ATP levels decrease leading to reduced Na+/K+ ATPase and 
sarcoplasmic reticulum (SR) Ca2+ pump activity and cystolic Na+ and Ca2+ retention. 
Additionally the decreasing oxygen supply during ischemia leads to an increased reliance 
on anaerobic glycolysis evident in the increased production of anaerobic-glycolysis by-
products and hydrogen ions (H+), thus decreasing cellular pH and lactate in the ischemic 
myocardium (van der Vusse et al. 1987). The increase in H+ in the myocardium promotes the 
activity of the sodium (Na+)/H+ exchanger leading to further increase in sodium retention, 
This is followed by calcium entry through the activity of the Na+/Ca2+ exchanger; increased 
Ca2+ opens the ryanodine receptor further increasing cytosolic Ca2+ referred to as Ca2+ 
overload (Cannell et al. 1995) triggering cell death. ROS production also promotes Ca2+ 
overload through its interaction with various Ca2+-related ion channels, including increasing 
the open probability of the ryanodine receptor found on the sarcoplasmic reticulum via 
oxidation of key thiol groups within the protein (Boraso & Williams, 1994), Ca2+ leakage 
through lipid perioxidation of phospholipid membranes (Burton et al.1990) and stimulation 
of the Na+-Ca2+ exchanger (Shi et al. 1989) through both lipid perioxidation and oxidation of 
thiol groups within the exchanger protein. 
Increased production of reactive oxygen species (ROS) (Arroyo et al., 1987; Steenbergen et 
al., 1987) during reperfusion triggers increased uncoupling of mitochondria complex I (Rolo 
and Palmeira, 2006, Tanaka et al., 2000). Additionally diabetes is associated with decreased 
antioxidant capacity measured by both direct enzyme activity by total plasma anti-oxidant 
capacity (TRAP) assay and indirectly by measures of lipid peroxidation such as lipid 
hydroperoxides and conjugate dienes (Likidlilid et al., 2007, Marra et al., 2002, Santini et al., 
1997; Santos et al., 2011) and calcium  overload  (Steenbergen et al., 1987),  leading to cell 
death and cardiac damage (Chen et al., 2002). Clinically, the Prevention of REStenosis with 
Tranilast and its Outcomes (PRESTO) trial found that diabetic patients had increased 
incidence of mortality and myocardial infarction 9 months after percutaneous coronary 
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intervention (Mathew et al., 2004). Diabetic patients with hypertension were at a greater risk 
of adverse outcomes following percutaneous coronary intervention (Lingman et al., 2011) 
Hyperglycaemia that is not controlled can lead to abnormal cardiac contractile dysfunction, 
with decreased Ca2+ sensitivity of contractile proteins. Animal studies show that there is 
increased post-translational modification of contractile proteins with phosphorylation of 
myofilament proteins troponin I and troponin T resulting in decreased Ca2+ sensitivity 
(Akella et al., 1995). Myocardial tissue collected from diabetic and non-diabetic patients 
undergoing coronary artery bypass surgery showed that the presence of diabetes decreased 
Ca2+ sensitivity (Jweied et al. 2005). Diabetic patients also have a higher risk of developing 
hypertension than normoglycaemic individuals. Sodium (Na+) retention has been identified 
as a possible cause of this increased risk of hypertension due to increased Na+ -glucose co-
transporter activity found in the renal tubules of diabetic patients (Nosadini et al., 1993). 
Hyperglycaemia and hypertension have an additive effect on long-term cardiovascular risk, 
and when both are present there is greater risk of microvascular complications, including 
nephropathy and retinopathy, and macrovascular complications such as atherosclerosis. 
During ischemia-reperfusion (refer Fig. 3), there is programmed loss of cardiomyocytes, 
apoptosis, with rates of 2–12% reported in the border zone of human myocardial infarcts 
(Ottaviani et al., 1999; Olivetti et al., 1996). This loss of viable tissue leads to structural 
remodelling of the heart and deteriorating cardiac function. Both acute stress 
hyperglycaemia (Suleiman et al., 2005) and diabetes (Mathew et al., 2004; Muhlestein et al., 
2003) aggravate injury following reperfusion of the ischemic myocardium. Hyperglycaemia 
increases cardiomyocyte apoptosis, both acutely as shown by recent studies (Wong et al. 
2011) as well as after prolonged exposure in diabetic animals (Fiordaliso et al. 2000; Sheu et 
al. 2007) and human tissue (Frustaci et al. 2000). Aggravated reperfusion injury correlates 
with increased apoptosis in the area at risk (Crow et al. 2004). Clinically, elevated but non-
diabetic blood glucose levels also increase cardiovascular mortality risk (Balkau et al. 1998).  
Apoptosis is up-regulated in hyperglycaemic cellular models of ischemia, where cardiac 
myocytes are deprived of serum and placed in hypoxic conditions (Bonavita, 2003, Aki et al., 
2010). Bonavita et al 2003 identified activation of pro-apoptotic mediators of Bid and Bax 
and down-regulation of anti-apoptotic mediator Bcl-xl in H9c2 rat cardiomyoblast cell line. 
Further support is provided by Aki et al. (2010) using H9c2 cells in hypoxic hyperglycaemic 
conditions that showed AIF release through ATP depletion promoting chromatin 
condensation and DNA fragmentation. Receptor for Advanced Glycation End products 
(RAGE) expression has been identified to be crucial to the promotion of apoptosis and 
reperfusion injury via increased c-Jun N-terminal Kinases (JNK) signalling promoting pro-
apoptotic caspase-3 activation and cytochrome-c release (Aleshin et al., 2008). 
As well as apoptosis, when cells have been exposed to sustained damage, there is necrosis of 
myocardial tissue, which is aggravated by hyperglycaemia. Hyperglycaemia-activated ROS 
promote the production of methylgloxal a side product of many metabolic pathways; 
increase in methygloxal promotes the NF- to bind to the promoter region of RAGE (Yao 
and Brownlee, 2010). Increased RAGE expression and increased induced nitric oxide 
synthase (iNOS) expression, increase nitric oxide production (NO) (Bucciarelli et al., 2006). 
NO and ROS species combine to form peroxynitrate, increasing high mobility group box 1 
(HMGB1) release, a marker of necrotic cell death, although mechanisms has not been 
defined (Loukili et al., 2011). 
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Fig. 3. Ischemia-reperfusion induced signal transduction pathway leading to apoptosis in 
cardiac myocytes. 
4. New treatment strategies during ischemic heart disease  
First line treatment for diabetes is anti-hyperglycaemic agents, with insulin the anti-
hyperglycaemic agent for type 1 diabetes and in some type 2 diabetes cases. Intensive 
glycaemic control clinically delayed development of microvascular complications in type 2 
diabetic patients in the United Kingdom Prospective Diabetes Study (UKPDS, 1998a), but 
did not lead to a reduction in cardiovascular events; a subgroup of patients treated with 
metformin had a 39% reduction in myocardial infarction, although there were only a small 
number of events. Patients with Type 1 diabetes in the Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study only 
showed a reduction in risk of any cardiovascular complications by 42% only years after 
recruitment (The Diabetes Control and Complications Trial/Epidemiology of Diabetes 
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Interventions and Complications Research Group, 2003). In the large randomised clinical 
trials, ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation) and ACCORD (Action to Control Cardiovascular 
Risk in Diabetes), intensive glycemic control compared to standard glucose-lowering targets 
in type 2 diabetes led to a reduction in risk for microvascular complications, although the 
optimum treatment for minimising the risk of cardiovascular complications was not 
defined. Metformin is routinely used in type 2 diabetes and has some cardiovascular 
benefits in obese type 2 diabetic patients (UKPDS, 1998b). In a pre-clinical study, acute stress 
hyperglycaemia aggravated infarct area and apoptosis following ischemia-reperfusion 
whereas perfusion with insulin decreased apoptosis and reduced reperfusion injury (Wong 
et al., 2011).  
4.1 GLP-1 agonists  
Glucagon-like peptide 1 (GLP-1) agonists are an exciting new class of anti-hyperglycaemic 
medication that not only lower glucose levels, but also reduce weight and have protective 
effects on pancreatic islets. Since the insulinotropic and insulinomimetic effects of GLP-1 are 
mitigated at plasma glucose concentrations of 3.9 mmol/L, this minimizes the risks of 
hypoglycemia and the need for glucose infusion. Therefore, the pharmacological properties 
of GLP-1 are attractive as a means to stimulate myocardial glucose uptake during post-
ischemic contractile dysfunction. Currently, there are limited clinical studies to confirm the 
impact of GLP-1 agonists on cardiovascular events in subjects with type 2 diabetes. 
Glucagon like peptide-1 (GLP-1) agonists, mimic the action of the incretin GLP-1 upon its 
binding to the GLP-1 receptor, which has been shown to be expressed in cardiomyocytes 
(Ban et al., 2008). GLP-1 also promotes the release of insulin, whilst inhibiting the release of 
glucagon, both these effects occur postprandial.  
Several animal studies involving murine and canine models have examined the effects of 
GLP-1 agonists on the ischaemic myocardium (Timmers et al. 2009; Noyan-Ashraf et al. 
2009; Kristensen et al. 2009; Ban et al. 2010). Most, but not all of these studies suggest that 
GLP-1 agonists may have beneficial effects on the myocardium following an ischemic insult. 
These benefits ranged from reduction in infarct size to improvement in left ventricular 
function, although the mechanisms for the cardio-protective action are not well understood. 
In addition, most studies used non-diabetic animal models, where the hearts were subjected 
to normal glucose levels and transient administration of GLP-1 agonists. In a recent study 
(Noyan-Ashraf et al. 2009), Liraglutide conferred cardio-protection over Metformin despite 
equivalent degrees of glycaemic control. In this study, diabetes was induced in mice by 
using streptozotocin, and therefore a model of Type I diabetes. The cardioprotective 
properties of GLP-1 agonist are independent of its glycaemic control properties and 
inactivate a key pro-apoptotic protein BAD mediated via PKB/AKT signalling, thus 
decreasing apoptosis and reperfusion injury (Timmers et al. 2009). The effects of GLP-1 on 
outcomes following acute coronary occlusion for subjects with Type 2 diabetes have yet to 
be defined.  
4.2 Mineralocorticoid receptor antagonists 
High plasma aldosterone levels during percutaneous coronary intervention double the risk 
of mortality and are an independent risk factor for mortality (Beygui et al. 2006). Pre-
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clinically the administration of aldosterone increased reperfusion injury by promoting 
apoptosis (Mihailidou et al., 2009). Aldosterone at inappropriate levels promotes 
inflammation and cardiovascular remodelling via activation of mineralocorticoid receptors 
(MR). Aldosterone has also been reported to trigger oxidative stress, inflammation, 
thrombosis and sudden cardiac death (Rajagopalan et al. 2002; Struthers 2001). ACE 
inhibitors or angiotensin receptor antagonists mitigate the cardiorenal complications of 
diabetes but do not suppress aldosterone production. Aldosterone levels increase 
(“aldosterone breakthrough”) in 10-53% patients, indicating aldosterone is an independent 
risk factor for myocardial damage.  
Recent studies show aldosterone interferes with insulin signalling pathways and reduces 
expression of insulin-sensitizing factors adiponectin and peroxisome proliferator activated 
receptor (Wada et al. 2009; Guo et al. 2008). Blockade of the mineralocorticoid receptor 
increased adiponectin and peroxisome proliferator-activated receptor- in adipose tissue 
leading to improved insulin sensitivity in obese, diabetic ob/ob and db/db mice (Guo et al. 
2008; Hirata et al. 2009). Further confirmation of cross talk between aldosterone and insulin 
signalling pathways is that insulin resistance improved with treatment in patients with 
primary hyperaldosteronism (Catena et al. 2006). Spironolactone has also been shown to be 
effective in decreasing albuminuria in patients with type 2 diabetes with proteinuria who 
were being treated with ACE inhibitors. (Davidson et al. 2008). Although the mechanism 
was not defined, an anti-inflammatory action was proposed. 
The relationship between aldosterone, glucose metabolism and insulin resistance is poorly 
explored. The results from RALES (Randomised ALdactone Evaluation Study), EPHESUS 
(Eplerenone Post acute Myocardial Infarction HEart Failure SUrvival and efficacy Study) 
[Pitt et al. 2003], and recently EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization 
and Survival Study in Heart Failure) provide strong evidence that preventing 
mineralocorticoid receptor activation increases survival and decreases hospitalization in 
patients with heart failure and acute myocardial infarction. In these trials 32% of patients 
were diabetic, highlighting a potential benefit of MR antagonist use to minimise 
cardiovascular complications in diabetic patients in addition to anti-hyperglycaemic 
treatment. Subgroup analysis of EPHESUS showed the beneficial effects of eplerenone were 
also found in patients with diabetes (O’Keefe et al. 2008). Diabetic patients treated with 
eplerenone had a higher rate of absolute risk reduction, compared with patients without 
diabetes, for both end-point of death from cardiovascular causes or hospitalization for 
cardiovascular events (5.1 vs. 3.5%). 
5. Conclusion 
There is an enormous public health problem emerging given the increasing aging 
population who are at highest risk of having an acute ischemic event and with diabetes the 
fastest growing disease, the proportion of people at risk of cardiovascular disease is 
therefore increasing dramatically. Globally health expenditure on diabetes is estimated to 
rise, with the health burden growing - currently 300 million people with diabetes 
worldwide, despite preventative strategies. Additional therapies are required and the 
results from clinical trials to determine the cardiovascular effects of the new anti-
hyperglycemic agents, GLP-1 agonists are eagerly anticipated. Mineralocorticoid receptor 
antagonists, spironolactone and eplerenone have demonstrated specific actions at low doses, 
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preventing end-organ damage. In particular, diabetic patients showed greater absolute 
cardiovascular risk reduction. Provided there is monitoring of plasma K+, there is potential 
for use of MR antagonists in diabetes. 
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